Difficult Cases in Lung SBRT
This is an education session which focuses on difficult cases in the use of lung SBRT. It includes a set of challenging cases followed by a short didactic session on each challenging topic. The cases/topics include: 1) SBRT for a large (>5 cm) primary, node negative tumor. This case addresses the use of adjuvant systemic therapy and safe delivery of SBRT for large tumors. 2) SBRT for an ultracentral lung tumor. This case addresses patient selection, risk/benefit analysis, dose constraints and expected outcomes when using SBRT for an ultracentral lung cancer. 3) SBRT in a patient with interstitial lung disease. This case addresses risks, benefits and alternatives to SBRT for ILD patients with lung cancer.
- Lung SBRT for Tumors Larger Than 5 cm
Megan E. Daly, MD
- SBRT for Ultracentral Lung Tumors
Meredith E. Giuliani, MD, PhD, MBBS, MEd
- SBRT in Patients With Interstitial Lung Disease and Q&A
Jeremy P. Harris, MD, MPhil
This activity is available from July 25, 2023, through 11:59 p.m. Eastern time on July 24, 2025.
This activity was originally recorded at the 2022 ASTRO Annual Meeting.
The activity is designed to meet the interests of medical oncologists, radiation oncologists, radiation physicists, radiation therapists and residents.
Upon completion of this activity, participants should be able to:
- Describe the appropriate use of lung SBRT in challenging clinical scenarios.
- Appropriately assess complex patients for lung SBRT and discuss the risks and benefits of lung SBRT with these patients.
Megan E. Daly, MD, is employed by University of California Davis Comprehensive Cancer Center and receives research support from NIH and clinical trial funding from the Department of Defense, Genentech, Merck, and EMD Serono. Dr. Daly serves on the Advisory Board and receives compensation from Boston Scientific and Novocure. She serves as an editorial board member for the Seminars in Oncology journal and the International Journal of Radiation Oncology Biology Physics.
Meredith E. Giuliani, MD, PhD, MBBS, MEd, is employed by the University of Toronto and Radiation Medicine Program, Princess Margaret Cancer Centre. Dr. Giuliani serves on the Advisory Board of AstraZeneca and Bristol Myers-Squibb. She receives research grant support from Eli Lilly and honoraria and travel expenses from Elekta, Inc. She serves in a leadership role as Chair of the Education committee for the Canadian Association of Radiation Oncology as well as serving as Senior Editor for the International Journal of Radiation Oncology Biology Physics.
Jeremy P. Harris, MD, MPhil, is employed by the University of California - Irvine.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until July 24, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.